• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, June 30

Pharmaceutical company Wanbury Ltd has posted over four times increase in net profit at Rs 11.31 crore (Rs 2.15 crore) for the fourth quarter ended March 31, 2007. Total sales rose 17.74 per cent to Rs 47.98 crore (Rs 40.75 crore). For the full fiscal, profit after tax rose 94.13 per cent to Rs 20.83 crore (Rs 10.73 crore) while sales increased 31.77 per cent to Rs 146.08 crore (Rs 110.86 crore). During the year, Wanbury launched CPINK, a product targeting iron deficiency anaemia during pregnancy, which earned Rs 11-crore revenue in the first year. The company’s new formulations department ‘Osteolife’ has also contributed Rs 4.2 crore to the top line and five new products were launched during this period. The numbers include the financials of the merged company ‘The Pharmaceutical Products of India Ltd’. —

More Stories on : Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
JM Financial full-year net up 36%; to pay Rs 5 dividend

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line